Skip to content

Study · Measured the body's own peptide · 1985

1 result

Changes in the somatostatin, substance P and vasoactive intestinal polypeptide content of the gastrointestinal tract following streptozotocin-induced diabetes in the rat.

Ballmann M, Conlon JM

Diabetologia1 Jun 1985Cited by 51 (Europe PMC)

PMID2412923 (opens in a new tab)DOI10.1007/bf00283143 (opens in a new tab)PepBankPUB-02412923
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Other

    In rats with streptozotocin-induced diabetes of 10 weeks' duration, gut VIP content was 54% higher than in control animals.

    In plain wordsIn diabetic rats, the body's own VIP in the gut was higher than in control rats.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseGut VIP content in streptozotocin diabetes
    Study

    ratn: not reported in source

    streptozotocin-induced diabetes
    Comparator
    Control animals
    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Measurements

    VIP content increase
    54%
    streptozotocin-diabetic rat gut

    Source sentences

    Summary
    The increase in the vasoactive intestinal polypeptide (VIP) content (54%, p less than 0.05)
    1 context sentence
    Summary · context
    Rats with streptozotocin-induced diabetes of 10 weeks' duration showed significant changes in the total content of somatostatin, substance P and vasoactive intestinal polypeptide in the stomach and small intestine compared with control animals.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.